Who are Teprotumumab N01's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/teprotumumab-n01.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Teprotumumab N01 — Competitive Intelligence Brief

Teprotumumab N01 (Teprotumumab N01) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IGF-1 receptor antagonist monoclonal antibody. Area: Immunology / Ophthalmology.

marketed IGF-1 receptor antagonist monoclonal antibody IGF-1R (Insulin-like Growth Factor-1 Receptor) Immunology / Ophthalmology Biologic Live · refreshed every 30 min

Target snapshot

Teprotumumab N01 (Teprotumumab N01) — Innovent Biologics (Suzhou) Co. Ltd.. Teprotumumab is a human monoclonal antibody that inhibits insulin-like growth factor-1 receptor (IGF-1R) signaling to reduce inflammation and fibrosis in thyroid eye disease.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Teprotumumab N01 TARGET	Teprotumumab N01	Innovent Biologics (Suzhou) Co. Ltd.	marketed	IGF-1 receptor antagonist monoclonal antibody	IGF-1R (Insulin-like Growth Factor-1 Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IGF-1 receptor antagonist monoclonal antibody class)

Innovent Biologics (Suzhou) Co. Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Teprotumumab N01 — Competitive Intelligence Brief. https://druglandscape.com/ci/teprotumumab-n01. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab